COA: Use of rhPDGF in a collagen matrix effective for foot and ankle fusion
Outcomes of Hindfoot and Ankle Fusions Treated with Augment Injectable Bone Graft: Results of a Prospective Randomized Controlled Trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
217 patients undergoing hindfoot and ankle reconstruction were randomized to receive either the Augment Injectable Bone Graft, containing platelet-derived growth factor (rhPDGF-BB in a tricalcium phosphate (B-TCP)/collagen matrix, or an autogenous bone graft to compare bone fusion and clinical success rates. Patients were to be assessed over a 1 year period; preliminary results indicated that fusi...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE